As U.S. drug shortages run rampant, lawmakers are getting creative with their attempts to ease the situation. | Under the ...
In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business ...
In a letter to FDA Commissioner Robert Califf, M.D., the House Committee on Oversight and Accountability chairman argued that China’s influence over global pharmaceutical supply chains constitutes an ...
Once hailed as a landmark accomplishment for the speed with which it was developed and a shining example of British innovation, the AstraZeneca coronavirus vaccine has been grounded by the European ...
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. “Every time we ...
Apellis’ geographic atrophy drug Syfovre delivered what CEO Cedric Francois called “robust” growth in the first quarter, as its sales topped analysts’ expectations. | Apellis’ geographic atrophy drug ...
After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France’s MedinCell are using the same playbook for a similar candidate. | The companies second go at a long-acting ...
Ennogen, a U.K.-based drug and device maker, reeled in a £30 million ($37.5 million) credit facility that the company will use to expand its international horizons. Santander U.K. is behind the loan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results